Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="75082" type="PERSON" weightage="20" keywordseo="Indian-mens-hockey-team">Indian men's hockey team</keyword> stormed into the <keyword id="6450929" type="UNKNOWN" weightage="20" keywordseo="olympic-games">Olympic Games</keyword> quarterfinal with a comprehensive 3-1 victory over defending champions Argentina in its penultimate pool match here on Thursday. After goalless first two quarters, India broke the deadlock in the 43rd minute through <keyword id="208870" type="PERSON" weightage="20" keywordseo="Varun-Kumar">Varun Kumar</keyword> before <keyword id="5893859" type="PERSON" weightage="20" keywordseo="vivek-sagar-prasad">Vivek Sagar Prasad</keyword> (58th) and <keyword id="630129" type="PERSON" weightage="20" keywordseo="Harmanpreet-Singh">Harmanpreet Singh</keyword> (59th) struck in the closing minutes of the match to seal the contest. Argentina's lone goal came from a penalty corner conversion by <keyword id="11743459" type="UNKNOWN" weightage="20" keywordseo="schuth-casella">Schuth Casella</keyword> in the 48th minute. By virtue of this win, India have consolidated their position in the second spot of <keyword id="2732146" type="COMPANY" weightage="20" keywordseo="Pool-A">Pool A</keyword> with three wins and one loss out of four games, behind Australia. Argentina are struggling at the fifth spot in the six-team pool and need to beat New Zealand in their final preliminary match on Friday to stay in the hunt for a quarterfinal berth. The top-four make the last-eight stage from each group. India will play hosts Japan in their final pool match on Friday. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/sony-sells-more-than-10-million-units-of-the-ps5-despite-supply-shortage-since-launch/articleshow/84848218.cms">Sony sells more than 10 million units of the PS5 despite supply shortage since launch</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/adani-group-tata-motors-bandhan-and-pnb-bank-bank-of-india-and-many-other-stocks-down-with-10-in-last-one-month/articleshow/84847887.cms">From Adani Group to Tata Motors and banks ⁠— these 17 stocks have already lost over 10% in last one month</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/careers/news/google-amazon-ibm-paytm-cognizant-hiring-business-analysts-across-the-country/articleshow/84847736.cms">Google, Amazon, IBM and many more are hiring business analysts across the country</a>

Tokyo Olympics: India beat Argentina 3-1 to enter the quarters in men's hockey

(Eds: Updating after discharge of players from hospital and incorporating SAI statement) New Delhi, Aug 17 () Six Indian men's hockey team players, including skipper Manpreet Singh, were on Monday discharged from a Bengaluru hospital after recovering from COVID-19. The Sports Authority of India (SAI) said in a statement that Manpreet, defender Surender Kumar, Jaskaran Singh, Varun Kumar, goalkeeper Krishan Bahadur Pathak and striker Mandeep Singh have been placed under quarantine at its Bengaluru centre after they were discharged from the hospital. "Manpreet Singh, Surender Kumar, Jaskaran Singh, Varun Kumar, Krishan B Pathak and Mandeep Singh, who had tested Positive for COVID-19 earlier this month and were later shifted to hospital as a precautionary measure and for better monitoring were discharged from hospital earlier today," the SAI said. "They are now under quarantine at Sports Authority of India's National Centre of Excellence (NCOE) in Bengaluru." Speaking about the health condition of the players, Dr Arun Kumar of SS Sparsh Multispeciality hospital in Bengaluru said, "All the six players have recovered fully and their vitals are absolutely stable. "They will be in quarantine at SAI's Bengaluru centre and will be given the anti-body test after 10 days to check if they have built immunity against the virus." All the six players are housed in the ground floor of the hostel, where other members of the camp have no access, the SAI said. "This is a precautionary measure to ensure there is no contact between the six players and the other campers over the next 10 days." The SAI said the rest of the players of the Indian hockey teams, men and women, will resume sporting activities from Wednesday as scheduled. Earlier, a SAI source had told that all the six players have tested negative twice and their vitals are normal. They returned positive for the virus between August 10 and 12. "All the hockey players have completely recovered from COVID-19 and will be discharged this evening," the source said. Although asymptomatic, Mandeep was the first to be shifted to the hospital by the SAI after a dip in his blood oxygen level. Later, Manpreet and four other players were also moved to the same hospital as a precautionary measure. Currently, 33 male and 24 female players are in Bengaluru for the camp. The light intensity national camp is expected to continue till September 30. All the women players tested negative in the on-arrival tests conducted by SAI. SSC PM PDS AH

Hockey players discharged from hospital after recovering from COVID-19

New Delhi, Aug 17 () Six Indian men's hockey team players, including skipper Manpreet Singh, have recovered from COVID-19 and will be discharged from a Bengaluru hospital on Monday evening. According a source close to the team, Manpreet, defender Surender Kumar, Jaskaran Singh, Varun Kumar, goalkeeper Krishan Bahadur Pathak and striker Mandeep Singh have tested negative twice and their vitals are normal. They tested positive for the infection between August 10 and 12. "All the hockey players have completely recovered from COVID-19 and will be discharged this evening," the source told . Although asymptomatic, Mandeep was the first to be shifted to the SS Sparsh Multi-speciality Hospital in Bengaluru by the Sports Authority of India (SAI) after a dip in his blood oxygen level. Later, Manpreet and four other players were also moved to the same hospital as a precautionary measure. The training camps for both the men and women teams will begin in Bengaluru from Wednesday. However, the six recovered players will have to serve some more time in solation before they join their teammates. Currently, 33 male and 24 female players are in Bengaluru for the camp. The light intensity national camp is expected to continue till September 30. "But as per the state government guidelines the recovered players will have to live in isolation inside SAI campus for a week to 10 more days before resuming practice," the source said. All the women players tested negative in the on-arrival tests conducted by SAI. SSC PM PM

Hockey players recover from COVID-19; to be discharged from hospital this evening

<div class="KonaFilter image-container display-table"><div><div class="image"></div></div></div><ul><li><a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> agreed to purchase Array BioPharma for $11 billion. </li><li><a href="https://markets.businessinsider.com/stocks/arry-stock">Array Biopharma </a>specializes in the development and commercialization of drugs to treat cancer and other high burden diseases. </li><li>There have been several large healthcare acquisitions in 2019 focused on drugs to treat cancer. </li></ul><a href="https://markets.businessinsider.com/stocks/arry-stock">Array BioPharma</a> rose more than 50% before the opening bell on Monday after <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> offered $11 billion to buy the biotechnology company.Pfizer is offering $48 a share for Array, which represents around a 62% premium from its closing price on Friday. The deal is expected to be closed in the second half of 2019, and will first to appear in earnings in 2022. The merger has been approved by the boards of both companies. Pfizer's share price remained relatively flat in pre-market trading. Pfizer's purchase of Array Biopharma will broaden its access to the specialized cancer drugs. Pfizer purchased Theracon, a rare-disease biotechnology company, earlier this May for $340 million. "The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry leading-franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers," Albert Bourla, chief executive officer of Pfizer, said in a <a href="http://investor.arraybiopharma.com/news-releases/news-release-details/pfizer-acquire-array-biopharma">press release</a> on Monday. This acquisition adds to a series of notable healthcare deals in 2019. In early June, one of Pfizer's biggest competitors, <a href="https://www.businessinsider.com/merck-dr-roy-baynes-on-keytruda-cancer-drug-uses-strategy-2019-6">Merck, paid $773 million for Tilos Therapeutics</a>, a privately-held biotechnology company working on new treatments for cancer.At the start of the year, <a href="https://www.businessinsider.com/inside-story-eli-lilly-8-billion-acquisition-of-loxo-oncology-2019-1">Eli Lilly &amp; Co., paid $8 billion to acquire Loxo Oncology,</a> a developer of highly selective medicines for cancer treatments. Varun Kumar, an analyst Cantor Fitzgerald said the Array deal was good news for oncology companies. "A common theme associated with these companies has been a clinically de-risked asset in late-stage trials and/or relatively well-defined commercial opportunities in a niche market," Kumar said. The push into cancer drugs is part of a broader strategy for Pfizer. In 2018, <a href="https://www.businessinsider.com/pfizer-and-glaxosmithkline-will-spin-off-advil-chapstick-and-emergen-c-2018-12">the pharmaceutical giant sold off billion-dollar brands</a> like Advil, ChapStick and Emergen-Co to focus on more complex medicines like cancer drugs. Array BioPharma is up more than 200% so far this year. <div class="KonaFilter image-container display-table"><div><div class="image"><a href="https://markets.businessinsider.com/stocks/arry-stock"></a></div></div></div><a href="http://www.businessinsider.com/intelligence/ai-in-us-healthcare?IR=T&amp;utm_source=businessinsider&amp;utm_medium=ctgr&amp;utm_term=ctgr_leadgen&amp;utm_content=dhealth_ctgr_leadgen&amp;utm_campaign=dhealth_ctgr_leadgen_ai_in_us_healthcare"></a></hr>

Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer

<div class="KonaFilter image-container display-table"><div><div class="image on-image">ShutterstockInvestors should bet on biotechs working on cancer treatments, according to Wall Street analysts.</div></div></div><ul class="summary-list"><li>US drug giant Pfizer just announced that it is acquiring biotech Array BioPharma for $11.4 billion. </li><li>This latest deal points to a trend of big companies snapping up cancer-focused biotechs, with Merck buying the cancer biotech Tilos Therapeutics for <a href="https://www.mrknewsroom.com/news-release/research-and-development-news/merck-acquire-tilos-therapeutics">up to $773 million</a> last week.</li><li>Investors should consider three biotechs that could get a boost from the trend, according to analysts at Stifel and Cantor Fitzgerald: Exelixis, Blueprint Medicines, and Mirati Therapeutics.</li><li><a href="https://www.businessinsider.com/prime?module=article&amp;area=summary">Click here for more BI Prime stories. </a></li></ul>Giant pharmaceutical company <a href="https://www.businessinsider.com/category/pfizer">Pfizer</a> just announced that it is buying the biotech Array BioPharma for $11.4 billion, a major deal that's only the latest example of big drugmakers snapping up cancer-focused biotechs. It's a trend that's well worth investors' attention, analysts at Cantor Fitzgerald and Stifel say. They point out three biotechs that could get a boost, either because of growth opportunities down the road for the biotechs or because they are potential deal targets. Pfizer's latest move is part of a wider trend among big drugmakers aimed at <a href="https://www.businessinsider.com/pfizer-array-biopharma-deal-speaks-to-cancer-drug-strategy-2019-6">expanding their portfolios of cancer treatments</a>, which have proven to be lucrative investments across the industry. Drugmaker GlaxoSmithKline bought up cancer drugmaker Tesaro for <a href="https://www.businessinsider.com/glaxosmithkline-tesaro-agree-to-51-billion-deal-2018-12">$5 billion</a> late last year, for instance, and Eli Lilly announced the <a href="https://www.businessinsider.com/eli-lilly-to-buy-loxo-oncology-in-8-billion-cancer-drug-deal-2019-1">acquisition of biotech Loxo Oncology</a> early this year.Array already sells a combination of two cancer drugs, Braftovi and Mektovi, for the skin cancer melanoma. The biotech is also testing the combination out in more than 30 research trials, including to treat colorectal cancer. Pfizer offered $48 per share for Array, representing a 62% premium to the stock's closing price as of June 14, pointed out analysts Varun Kumar and Alethia Young at <a href="https://cantor2.bluematrix.com/sellside/EmailDocViewer?encrypt=69b1b002-8a25-4ce5-872d-16efa06c197a&amp;mime=pdf&amp;co=cantor2&amp;id=ecourt@businessinsider.com&amp;source=mail">Cantor Fitzgerald</a>. And the development should boost other companies developing similar, "targeted" cancer drugs that home in on things like a specific gene mutation in order to better treat cancer, they said.Read more: <a href="https://www.businessinsider.com/pfizer-array-biopharma-deal-speaks-to-cancer-drug-strategy-2019-6">Pfizer just struck an $11 billion deal, and it marks an ambitious shift in the US drug giant's blockbuster cancer strategy</a>Across these deals, a common theme is that companies have been eyeing drugs with strong research data that are in late stages of development, "and/or relatively well-defined commercial opportunities in a niche market," they said. Here are three other cancer biotech companies that could also get a boost, according to Wall Street analysts.Get the latest Pfizer stock price<a href="http://markets.businessinsider.com/stock/pfe-Quote"> here.</a>

3 biotechs that investors should buy next after Pfizer's $11 billion deal for cancer drugmaker Array BioPharma

<div class="KonaFilter image-container display-table"><div><div class="image"></div></div></div><ul class="summary-list"><li>US drug giant Pfizer just announced that it is buying cancer biotech Array BioPharma for about $11 billion.</li><li>Pfizer has been betting heavily that new cancer drugs will be <a href="https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1">key to its future growth</a>.</li><li>The latest deal marks a shift for the company into two new, important areas: the skin cancer melanoma and colorectal cancers that start in the colon or rectum. </li><li><a href="https://www.businessinsider.com/prime?module=article&amp;area=summary" target="_blank" rel="noopener">Click here for more BI Prime stories</a>.</li></ul>US drug giant Pfizer, which has been charting an expansion into cancer, just struck a deal to buy cancer biotech <a href="https://www.arraybiopharma.com/">Array BioPharma</a> for roughly $11 billion.The deal, Pfizer's biggest since 2016, represents a big investment into finding treatments for two types of cancer the drugmaker hadn't previously focused on: the skin cancer melanoma and colorectal cancers, which start in either the colon or rectum. Pfizer had largely honed in on breast and prostate cancers, cancer chief Andy Schmeltz <a href="https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1">told Business Insider</a> earlier this year.Both melanoma and colorectal cancers are common, with an estimated 145,600 and 96,480 new US cases expected this year, respectively, according to the <a href="https://www.cancer.gov/types/common-cancers">National Cancer Institute</a>.Cancer has become a <a href="https://www.businessinsider.com/merck-dr-roy-baynes-on-keytruda-cancer-drug-uses-strategy-2019-6">major area of investment</a> for pharmaceutical companies with the advent of cutting-edge technology justifying sky-high prices."Through the proposed acquisition of Array, Pfizer will set the stage to establish an industry-leading colorectal franchise with a potentially first and best-in-class combination that could have blockbuster revenue potential," Schmeltz said on Monday as part of a conference call about the Array BioPharma deal. "This will further augment our existing leading positions in both breast cancer and prostate cancer."Read more: <a href="https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1">Pfizer has a new strategy for fighting cancer that could generate $5 billion a year. We got a look inside.</a><h2>A push further into 'targeted' cancer drugs</h2>Array BioPharma makes "targeted" drugs that are developed for patients with certain types of cancer, like those who have tumors with certain gene mutations, in hopes of better fighting off the disease. That approach has been a big focus in the biopharmaceutical industry. It's part of a boom of similar, "personalized medicine" approaches that are tailored to an individual's disease and made possible by advances like faster genetic testing. Array BioPharma's combination of two drugs, Braftovi and Mektovi, was approved in the US last year to treat a serious, deadly type of melanoma. It could also be tested out in combinations with Pfizer's portfolio of medicines, the drug giant said on Monday. Array has also been testing the combination out in a type of colorectal cancer, where Pfizer says it has "blockbuster revenue potential."Data that Array released last month in colorectal cancer was described as "impressive" and favorable for approval by US regulators, Cantor Fitzgerald analysts Varun Kumar and Alethia Young said then. On the Monday call, Pfizer executives pointed in particular to the melanoma and colorectal cancer opportunities as a reason motivating the acquisition.<div class="KonaFilter image-container display-table"><div><div class="image"></div></div></div>Analysts like UBS's Navin Jacob said the deal made sense strategically, "given Pfizer's focus &amp; marketed portfolio of targeted cancer products."Jacob pointed, for instance, to the company's Xalkori drug for lung cancer. A targeted therapy, Xalkori is one of a handful of crucial cancer drugs for Pfizer, bringing in $524 million in revenue for the pharmaceutical company last year. Pfizer has so far staked out expertise in two types of cancer, breast cancer and prostate cancer, through the flagship drugs Ibrance and Xtandi, respectively. The company planned to keep those two in focus, Pfizer's Schmeltz told Business Insider <a href="https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1">earlier this year</a>. "We're trying to be thoughtful that, given the unmet need in oncology, you can't have deep expertise and capability in everything across oncology," he <a href="https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1">said then. </a><ul class="read-more-links"><li>Read more:</li><li><a href="https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1">Pfizer has a new strategy for fighting cancer that could generate $5 billion a year. We got a look inside.</a></li><li><a href="https://www.businessinsider.com/merck-dr-roy-baynes-on-keytruda-cancer-drug-uses-strategy-2019-6">Drug giant Merck just bought a biotech for $773 million, and it reveals the company's strategy for keeping on top in cancer treatments</a></li><li><a href="https://www.businessinsider.com/what-is-biotechnology-introductory-classes-for-nonscientists-2019-5">We took the two-day, $1,300 'biotech for dummies' class where healthcare executives, HR managers, and investors catch up on science for the first time since high school</a></li><li><a href="https://www.businessinsider.com/new-ceos-advice-from-sheila-gujrathi-ceo-of-gossamer-bio-2019-6">The woman who founded $1 billion biotech Gossamer told us about the 3 jobs that prepared her to be a first-time CEO</a></li></ul><a href="http://www.businessinsider.com/intelligence/ai-in-us-healthcare?IR=T&amp;utm_source=businessinsider&amp;utm_medium=ctgr&amp;utm_term=ctgr_leadgen&amp;utm_content=dhealth_ctgr_leadgen&amp;utm_campaign=dhealth_ctgr_leadgen_ai_in_us_healthcare"></a></hr>

You Searched For "Varun Kumar" and got 7 results

Tokyo Olympics: India beat Argentina 3-1 to enter the quarters in men's hockey

PTI

Hockey players discharged from hospital after recovering from COVID-19

PTI

Hockey players recover from COVID-19; to be discharged from hospital this evening

PTI

Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer

Daniel Strauss

3 biotechs that investors should buy next after Pfizer's $11 billion deal for cancer drugmaker Array BioPharma

Clarrie Feinstein,Emma Court

Pfizer just struck an $11 billion deal, and it marks an ambitious shift in the US drug giant's blockbuster cancer strategy

Emma Court

17 Crazy Facts That Sound Fake But Are Actually True

Megan Willett

Popular Keywords

Buying Guides